CHLA Clinical Research Studies

Having volunteers participate in research studies and clinical trials is critical to our research efforts. Thousands of children and families are involved in our patient-centered studies every year. Many of the treatments used today are based on the results of past research studies and clinical trials conducted with our patients. Our scientific and clinical experts take the best ideas from the laboratory -- to the patient -- in the form of promising new treatments.

By searching our study directory, you may identify research that could impact the life of your child or of another child you know. Because the number of available research studies and clinical trials for children nationwide is small, every participant makes a significant contribution.

In addition to enrolling children with certain diseases in order to study treatments and prevention of those diseases, we also need to study healthy children. Ask your child’s doctor about volunteer study options that may be suitable for your child.

Please contact the study staff listed in your search results for more information.

Search by Keyword:    

Back to the full listing

Study Details - ID: CHLA-16-00044
Health/Science/Disease Category:
Relapsed Acute Lymphoblastic Leukemia (ALL)
Purpose of Research:
This study aims to evaluate the side effects (good and bad) of giving Vincristine Suflate Liposome Infection (also known as Marqibo®) - a drug approved for leukemia treatment in adults but that is experimental in children - with other standard chemotherapy drugs and to measure how effective the combination is at treating children and young adults with leukemia that has come back after initial treatment.
Short Name:
TACL Marqibo® ALL study
Full Title of Study:
T2012-002: A Pilot Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination with UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults with Relapse of Acute Lymphoblastic Leukemia
Phase/Type of Study:
Phase I drug treatment
Age 1 to 21 with leukemia (ALL) that has returned after an initial response to treatment
Time Commitment/Requirements:
Treatment on this study consists of approximately 4 weeks of chemotherapy
Primary Investigator:
Dr. Alan Wayne
Coordinator Contact Name:
Ellynore Florendo, CCRC or Meg Fender, CRC -III
Phone Number:
Clinical Trials .Gov Identifier: